Abcam, ab222512, Anti-Claudin 18.2 antibody [EPR19202]

Size: 20µL / 100µL / 1mL
Anti-Claudin 18.2 antibody [EPR19202] (ab222512) is a rabbit monoclonal antibody detecting Claudin 18.2 in IHC-P, IHC-Fr . Suitable for Human, Mouse, Rat . - Clone EPR19202 is the most cited clone to Claudin 18.2 - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR19202,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, IHC-FrSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Anti-Claudin 18.2 antibody [EPR19202] (ab222512) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-Fr and IHC-P
Abcam's high quality manufacturing and validation processes ensure Anti-Claudin 18.2 antibody [EPR19202] (ab222512) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-Claudin 18.2 antibody [EPR19202] (ab222512) specifically detects Claudin 18.2 (UniProt ID: P56856; Molecular weight: 28kDa) and is sold in 100 µL and 1 mL selling sizes.
Conjugation-ready, carrier free format available for antibody clone EPR19202 -
ab240400
Antibody clone EPR19202 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor
488, Alexa Fluor
647, Alexa Fluor
594, Alexa Fluor
568, Alexa Fluor
555, Alexa Fluor
ab311014
ab311142
ab311779
ab313060
ab313260
ab321409
Claudin 18.2 (CLDN18.2) is a highly selective protein found in the tight junctions of gastric epithelial cells. It becomes accessible on the surface of tumor cells during malignant transformation, making it a valuable target for cancer therapy. CLDN18.2 is predominantly expressed in gastric and gastroesophageal cancers but is also found in other solid tumors. Researchers are developing targeted therapies, including monoclonal antibodies, bispecific antibodies and CAR-T cells, to exploit CLDN18.2's unique expression pattern. These therapies show promise in improving treatment outcomes for patients with CLDN18.2-positive cancers.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Claudin 18.2 also known as claudin 18 CLDN18 or claudin-18.2 is a tight junction protein with a molecular mass of approximately 27 kDa. It is primarily expressed in gastric epithelial cells and certain lung tissues. Claudin 18.2 is part of the claudin family which plays a critical role in forming tight junctions to regulate paracellular transport and maintain cellular polarity. This isoform specifically expressed in the stomach is encoded by the CLDN18 gene located on chromosome 3. Researchers often use techniques like Immunohistochemistry (IHC) referred to as claudin 18.2 IHC or cldn18 IHC to study its expression and localization.
Biological function summary
Claudin 18.2 functions within tight junction complexes creating a barrier and controlling the movement of ions and molecules between cells. It is vital for the integrity and function of epithelial cell barriers in the stomach. The protein interacts with other claudins and cytoplasmic proteins to form these tight junctions essential for maintaining tissue organization and permeability. Its unique expression pattern makes it a significant marker for gastric tissue and a potential target for therapeutics.
Pathways
Claudin 18.2 is involved in cellular pathways related to adhesion and barrier function. It plays a role in the tight junction pathway critical for epithelial barrier integrity. This pathway involves interactions with other claudin proteins and ZO-1 which is a cytoplasmic plaque protein that links claudins to the actin cytoskeleton reinforcing cellular structure. Another pathway where claudin 18.2 is important is the gastro-intestinal epithelium maintenance pathway which is fundamental for protecting gastric tissues.
Claudin 18.2 is a notable target in cancers especially gastric cancer. Its specific expression in gastric tissues makes it an attractive target for cancer immunotherapy as aberrant expression could indicate gastric cancer onset. Another disorder related to claudin 18.2 is asthma particularly where lung epithelial cells express this protein. Studies have identified links between claudin 18.2 and increased permeability in lung tissues implicating it in asthmatic pathophysiology. Its association with these conditions highlights the potential for claudin 18.2 as a diagnostic or therapeutic target in oncology and respiratory diseases.